scholarly journals EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations

2021 ◽  
Vol 35 (2) ◽  
pp. 281-317
Author(s):  
A. Nast ◽  
C. Smith ◽  
P.I. Spuls ◽  
G. Avila Valle ◽  
Z. Bata‐Csörgö ◽  
...  
Keyword(s):  
Psoriasis Vulgaris ◽  
Systemic Treatment

scholarly journals EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations

2020 ◽  
Vol 34 (11) ◽  
pp. 2461-2498
Author(s):  
A. Nast ◽  
C. Smith ◽  
P.I. Spuls ◽  
G. Avila Valle ◽  
Z. Bata‐Csörgö ◽  
...  
Keyword(s):  
Psoriasis Vulgaris ◽  
Systemic Treatment

HLA-G 14-bp polymorphism: a possible marker of systemic treatment response in psoriasis vulgaris? Preliminary results of a retrospective study

2014 ◽  
Vol 27 (5) ◽  
pp. 284-289 ◽  
Author(s):  
Alessandro Borghi ◽  
Roberta Rizzo ◽  
Monica Corazza ◽  
Alberto Maria Bertoldi ◽  
Daria Bortolotti ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Treatment Response ◽  
Psoriasis Vulgaris ◽  
Systemic Treatment ◽  
Preliminary Results ◽  
G 14

Topical treatment of chronic dermatoses with kertoplastic agents

2016 ◽  
Vol 19 (3) ◽  
pp. 170-172
Author(s):  
O. V Grabovskaya ◽  
E. Yu Vertieva ◽  
L. A Shestakova ◽  
Ekaterina V. Grekova
Keyword(s):  
Atopic Dermatitis ◽  
Topical Treatment ◽  
Psoriasis Vulgaris ◽  
Skin Diseases ◽  
Systemic Treatment ◽  
Skin Condition ◽  
Results Of Treatment ◽  
Severity Of The Disease

Atopic dermatitis and psoriasis are common chronic dermatosis characterized by prolonged recurrent course. Depending on the severity of the disease topical and systemic treatment are applied. Keratoplastic agents play an important role in treatment of skin diseases. These agents include Naftalan Cream 30%, which significantly improves the skin condition. The results of treatment of 10 patients with atopic dermatitis and 10 patients with psoriasis vulgaris Naftalan cream 30% are presented.

scholarly journals EVALUATION OF THE EFFECTIVENESS OF TOPICAL TREATMENT COMBINATION OF BETAMETHASONE DIPROPIONATE 0.05%/CALCIPOTRIOL MONOHYDRATE 0.005% GEL AND CLOBETASOLE PROPIONATE 0.05% OINTMENT IN PATIENTS WITH PSORIATIC ONYCHODYSTROPHY

2019 ◽  
Vol 22 (5-6) ◽  
pp. 156-160
Author(s):  
Ivan S. Maximov ◽  
N. G Kochergin ◽  
V. S Novoselov ◽  
D. I Ushakova
Keyword(s):  
Therapeutic Response ◽  
Psoriasis Vulgaris ◽  
Systemic Treatment ◽  
Betamethasone Dipropionate ◽  
Nail Psoriasis ◽  
Group A ◽  
Cutaneous Form ◽  
Hardware Processing ◽  
Group B

Psoriatic onychodystrophy is a comorbidity that often occurs in patients with psoriasis, affecting their quality of life. Although success has recently been achieved in the treatment of the cutaneous form of psoriasis, there are few publications about nail therapy with proven effectiveness. The development of effective and safe therapies remains relevant for nail psoriasis. Objective. to evaluate the effectiveness and tolerability of the fixed combination of betamethasone dipropionate 0.05%/calcipotriol monohydrate 0.005% gel and clobetasole propionate 0.05% ointment in patients with psoriatic onychodystrophy. Material and methods. the study included 50 patients with psoriasis vulgaris, mild to moderate severity with lesions of the nail plates. Patients were divided into two groups and used betamethasone dipropionate 0.05%/calcipotriol monohydrate 0.005% gel (group A) and clobetasole propionate 0.05% ointment with occlusion (group B) for 24 weeks with hardware treatment of nail plates at 0, 8, 16 weeks. They did not receive any other local or systemic treatment. The severity of nail psoriasis was assessed by the NAPSI index at week 0, 8, 16, and 24, and by the IGA after treatment. results. 43 patients completed the study. At the beginning of the study, the average NAPSI was 32.8 ± 10.3 in group A and 33.1 ± 9.8 in group B. At week 24 the average NAPSI score decreased to 12.8 ± 7.2 in group A and 11.8 ± 68 in group B. IGA for evaluation treatment score was 3 ± 0.74 in group A and 3.1 ± 0.79 in group B. Conclusions. Combined treatments in the form of hardware processing nail plates with betamethasone dipropionate 0.05%/calcipotriol monohydrate 0.005% gel and clobetasol propionate 0.05% ointment are effective and can be used in patients with moderate and severe nail psoriasis, which is confirmed by the results in clinical improvement of 60.8% and 64.5%, respectively, based on a decrease in NAPSI at 24 weeks and an assessment of the therapeutic response after treatment using the IGA.

S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 1 – Systemic treatment

2018 ◽  
Vol 16 (5) ◽  
pp. 645-669 ◽  
Author(s):  
Alexander Nast ◽  
Lasse Amelunxen ◽  
Matthias Augustin ◽  
Wolf‐­Henning Boehncke ◽  
Corinna Dressler ◽  
...  
Keyword(s):  
Psoriasis Vulgaris ◽  
Systemic Treatment ◽  
Short Version ◽  
S3 Guideline

scholarly journals Relationship between etanercept and thyroid function in patients with psoriasis vulgaris

2018 ◽  
Vol 91 (1) ◽  
pp. 42-47
Author(s):  
Iulia Ioana Roman ◽  
Teodora Mocan ◽  
Meda-Sandra Orasan ◽  
Elena Mihaela Jianu ◽  
Carmen-Angela Sfrangeu ◽  
...  
Keyword(s):  
Serum Level ◽  
Psoriasis Vulgaris ◽  
Systemic Treatment ◽  
Significant Negative Correlation ◽  
Thyroid Stimulating Hormone ◽  
Tnf Alpha ◽  
Significant Difference ◽  
Psoriasis Therapy ◽  
The Mean

Background and aim. Psoriasis vulgaris, a chronic inflammatory skin disease, requires a long term medication, in order to avoid relapsing episodes. TNF-alpha, one of the targeted molecule in psoriasis therapy, seems to be also involved in thyroid disorders etiopathogenesis. The aim of this study was to evaluate the relationship between anti TNF-alpha therapy and thyroid parameters: serum level of triiodothyronine (T3), free thyroxine (FT4), thyroid-stimulating hormone (TSH) and antithyroidperoxidase antibody (AbTPO) in psoriasis treated population.Methods. The study was performed on 44 patients with psoriasis vulgaris (20 patients under antiTNF-alpha treatment (etanercept), 24 patients with no previous systemic therapy). Serum concentrations of hormones, AbAntiTPO and TNF-alpha were measured and a thyroid ultrasonographic evaluation was performed for each patient.Results. The mean serum level of FT4 was significantly higher in patients with no systemic treatment (p<0.05). The patients treated with etanercept had a significantly higher level of TNF-alpha (p<0.05). No significant difference was observed for the other evaluated parameters. Also, we found a significant negative correlation between TNF-alpha and TSH levels (r=-0.366, p=0.015).Conclusions. We only found that the mean level of FT4 was significantly higher in patients with no systemic treatment. Also, a negative strong correlation was seen between serum level of TSH and TNF-alpha. Based on our data, comparison with other anti TNF-alpha therapies might be of interest in future studies.

Sign in / Sign up

Export Citation Format

Share Document